Gut bacterial tyrosine decarboxylases restrict the bioavailability of levodopa, the primary treatment in Parkinson’s disease
Sebastiaan P. van Kessel, Alexandra K. Frye, Ahmed Osama EL-Gendy, Maria Castejón, Ali Keshavarzian, Gertjan van Dijk, Sahar El Aidy
This study shows gut bacteria convert L-DOPA to dopamine, reducing its bioavailability and explaining variable dosing needs in Parkinson’s patients.
Nature Communications · Jan 14, 2019Peer-reviewedMolecular Biology